Home > Back to Publisher > Report Information

United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

GlobalData
January 16, 2012
520 Pages - SKU: GBDT6771758

Abstract Table of Contents Search inside this report Related Reports

United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, “United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the United States In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
2010 company shares and distribution shares data for each of the seven market categories.
Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket.
Key players covered include Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.
Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

1 Table of Contents: 1.1 List of Tables; 1.2 List of Figures
2 Introduction: 2.1 What is This Report About?
3 In Vitro Diagnostics In United States: 3.1 In Vitro Diagnostics, Market Segmentation; 3.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017; 3.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2010; 3.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2010; 3.5 In Vitro Diagnostics, United States, Company share (2009-2010)
4 Clinical Chemistry In United States: 4.1 Clinical Chemistry, Market Segmentation; 4.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2010; 4.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2010; 4.4 Clinical Chemistry Overall Revenue (2003-2017); 4.5 Clinical Chemistry Distribution Share (2009-2010); 4.6 Clinical Chemistry, United States, Company share (2009-2010)
5 Genetic Testing In United States: 5.1 Genetic Testing, Market Segmentation; 5.2 Genetic Testing Market, United States, Revenue Mix ($m), 2010; 5.3 Genetic Testing Market, United States, Segment Contribution (%), 2010; 5.4 Genetic Testing Overall Revenue (2003-2017); 5.5 Genetic Testing Distribution Share (2009-2010); 5.6 Genetic Testing, United States, Company share (2009-2010)
6 Haematology In United States: 6.1 Haematology, Market Segmentation; 6.2 Haematology Market, United States, Revenue Mix ($m), 2010; 6.3 Haematology Market, United States, Segment Contribution (%), 2010; 6.4 Haematology Overall Revenue (2003-2017); 6.5 Haematology Distribution Share (2009-2010); 6.6 Haematology, United States, Company share (2009-2010)
7 Histology And Cytology In United States: 7.1 Histology and Cytology, Market Segmentation; 7.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2010; 7.3 Histology And Cytology Market, United States, Segment Contribution (%), 2010; 7.4 Histology And Cytology Overall Revenue (2003-2017); 7.5 Histology And Cytology Distribution Share (2009-2010); 7.6 Histology And Cytology, United States, Company share (2009-2010)
8 Immuno Chemistry In United States: 8.1 Immuno Chemistry Market, United States, Revenue Mix ($m), 2010; 8.2 Immuno Chemistry Market, United States, Segment Contribution (%), 2010; 8.3 Immuno Chemistry Overall Revenue (2003-2017); 8.4 Immuno Chemistry Distribution Share (2009-2010); 8.5 Immuno Chemistry, United States, Company share (2009-2010)
9 Infectious Immunology In United States: 9.1 Infectious Immunology, Market Segmentation; 9.2 Infectious Immunology Market, United States, Revenue Mix ($m), 2010; 9.3 Infectious Immunology Market, United States, Segment Contribution (%), 2010; 9.4 Infectious Immunology Overall Revenue (2003-2017); 9.5 Infectious Immunology Distribution Share (2009-2010); 9.6 Infectious Immunology, United States, Company share (2009-2010)
10 Microbiology Culture In United States: 10.1 Microbiology Culture, Market Segmentation; 10.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2010; 10.3 Microbiology Culture Market, United States, Segment Contribution (%), 2010; 10.4 Microbiology Culture Overall Revenue (2003-2017); 10.5 Microbiology Culture Distribution Share (2009-2010); 10.6 Microbiology Culture, United States, Company share (2009-2010)
11 Overview of Key Companies in United States In Vitro Diagnostics Market: 11.1 Abbott Laboratories; 11.2 Siemens Healthcare; 11.3 F. Hoffmann-La Roche Ltd.; 11.4 Beckman Coulter, Inc.; 11.5 Ortho-Clinical Diagnostics Inc.; 11.6 bioMerieux S.A.; 11.7 Becton, Dickinson and Company; 11.8 Bio-Rad Laboratories, Inc.; 11.9 Alere Inc.; 11.10 Sysmex Corporation; 11.11 Qiagen N.V.; 11.12 Gen-Probe Incorporated; 11.13 DiaSorin S.p.A; 11.14 Thermo Fisher Scientific Inc.; 11.15 Immucor, Inc.; 11.16 Hologic, Inc.; 11.17 Phadia AB; 11.18 Cepheid; 11.19 Grifols, S.A.; 11.20 Life Technologies Corporation; 11.21 PerkinElmer, Inc.; 11.22 HORIBA, Ltd.; 11.23 OraSure Technologies, Inc.; 11.24 Danaher Corporation; 11.25 Abbott Laboratories
12 In Vitro Diagnostics Market Pipeline Products: 12.1 Clinical Chemisty Market Pipeline Products; 12.2 Immuno Chemistry Market Pipeline Products; 12.3 Haematology Market Pipeline Products; 12.4 Infectious Immunology Market Pipeline Products; 12.5 Microbiology Culture Market Pipeline Products; 12.6 Histology and Cytology Market Pipeline Products; 12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape: 13.1 Merger; 13.2 Acquisition; 13.3 Partnerships
14 Recent Developments: 14.1 Strategy and Business Planning; 14.2 Legal and Regulatory; 14.3 Government and Public Interest; 14.4 Product News
15 Appendix: 15.1 Definitions of Markets Covered in the Report; 15.2 Research Methodology; 15.3 Secondary Research; 15.4 Primary Research; 15.5 Models; 15.6 Forecasts; 15.7 Expert Panels; 15.8 GlobalData Consulting; 15.9 Contact Us; 15.10 Disclaimer
1.1 List of Tables: Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017; Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2010; Table 3: In Vitro Diagnostics, United States, Cross-Category Analysis, 2003-2017; Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Table 6: In Vitro Diagnostics, United States, Company share by Revenue ($m), USD Actual, 2009-2010; Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2010; Table 8: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 9: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 12: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 13: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 15: Clinical Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2010; Table 17: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 18: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 20: Genetic Testing, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 21: Haematology Market, United States, Segment Contribution (%), 2010; Table 22: Haematology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 23: Haematology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 24: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 25: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 26: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 27: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 28: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 29: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 30: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 31: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 32: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 33: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 35: Haematology, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2010; Table 37: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 38: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 40: Histology And Cytology, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2010; Table 42: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 43: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 44: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 45: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 48: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 49: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 50: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 51: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 52: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 53: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 54: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 55: Immuno Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 56: Infectious Immunology Market, United States, Segment Contribution (%), 2010; Table 57: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 58: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 59: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 60: Infectious Immunology, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 61: Microbiology Culture Market, United States, Segment Contribution (%), 2010; Table 62: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Table 63: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Table 64: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Table 65: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Table 66: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010; Table 67: Microbiology Culture, United States, Company share by Revenue ($m), USD Actual 2009-2010; Table 68: Clinical Chemisty Market Pipeline Products; Table 69: Immuno Chemistry Market Pipeline Products; Table 70: Haematology Market Pipeline Products; Table 71: Infectious Immunology Market Pipeline Products; Table 72: Microbiology Culture Market Pipeline Products; Table 73: Histology and Cytology Market Pipeline Products; Table 74: Genetic Testing Market Pipeline Products; Table 75: Transonic Systems Merges With Scisense; Table 76: Vivakor Enters Into Memorandum Of Understanding To Merge With Resolution Biomedical; Table 77: Pall Corporation To Acquire ForteBio; Table 78: Shionogi Acquires Remaining 13% Joint Venture Stake In Ezose Sciences; Table 79: Agilent Technologies Completes Acquisition Of BioSystem Development; Table 80: Affymetrix To Acquire eBioscience For $330 Million; Table 81: AMAG Pharmaceuticals Plans For Sale Of The Company; Table 82: Vermillion Completes Acquisition Of Correlogic Systems For $0.4 Million; Table 83: Evonik Industries Acquires SurModics Pharmaceuticals From SurModics For $30 Million; Table 84: Everist Genomics Acquires Angiologix; Table 85: WuXi PharmaTech Acquires Abgent; Table 86: OPKO Health Acquires Claros Diagnostics; Table 87: Miraca Holdings Completes Acquisition Of Caris Diagnostics From Caris Life Sciences For $725 Million; Table 88: Bio-Rad Laboratories Acquires QuantaLife For $162 Million; Table 89: Sony Corporation of America Acquires Micronics; Table 90: PerkinElmer Completes Acquisition Of Caliper Life Sciences For $600 Million; Table 91: Thermo Fisher Scientific Acquires Intrinsic Bioprobes; Table 92: EMD Millipore To Acquire Amnis; Table 93: Thermo Fisher Scientific Acquires TREK Diagnostic Systems; Table 94: Solstas Lab Partners Acquires NextWave Diagnostic Laboratories; Table 95: Solstas Lab Partners Acquires Wilmington Pathology Laboratory; Table 96: Signal Genetics Acquires DiagnoCure Oncology Laboratories; Table 97: Luminex Completes Acquisition Of EraGen Biosciences; Table 98: Solstas Lab Partners Acquires Select Diagnostics; Table 99: BioMedical Technology Solutions Holdings To Acquire SharpsMD And 2000 Plus Consulting; Table 100: Nestle Health Science Completes Acquisition Of Prometheus Laboratories; Table 101: Abcam Acquires MitoSciences; Table 102: Health Diagnostic Laboratory Acquires Harris Scientific; Table 103: EKF Diagnostics Completes Acquisition of Stanbio Laboratory; Table 104: PositiveID Completes Acquisition Of MicroFluidic Systems; Table 105: Navitar Life Sciences To Acquire Modulation Optics; Table 106: Myriad Genetics Acquires Rules-Based Medicine; Table 107: Shrink Nanotechnologies To Acquire Nanopoint; Table 108: Novelos Therapeutics Acquires Cellectar; Table 109: LabCorp Completes Acquisition Of Orchid Cellmark For $85 Million; Table 110: HistoRx Enters Into Licensing Agreement With Yale University; Table 111: BioTime Enters Into Distribution Agreement With USCN Life Science; Table 112: Critical Path Institute Signs Memorandum Of Understanding With The Hamner Institutes; Table 113: Tyrian Diagnostics Enters Into Distribution Agreement With NeoClone; Table 114: Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics; Table 115: Lineagen Enters Into Co-Development Agreement With Fast Forward; Table 116: Pathogenetix Enters Into Co-Development Agreement With Sagentia; Table 117: Bio-Rad Expands Co-Marketing Agreement With Siemens Medical; Table 118: Ezose Sciences Enters Into Co-Development Agreement With Merck; Table 119: Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore; Table 120: Roche Enters Into Technology Integration Agreement With Labcyte; Table 121: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies; Table 122: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals; Table 123: Olink Bioscience Enters Into Distribution Agreement With Bethyl Laboratories; Table 124: SuperNova Diagnostics Enters Into Co-Development Agreement With Concile; Table 125: OncoSec Medical Enters Into Research Agreement With Serametrix; Table 126: Bruker Enters Into Co-Development Agreement With Lawrence Berkeley National Laboratory; Table 127: Dako Enters Into Co-Development Agreement With Bristol-Myers; Table 128: Transgenomic Enters Into Distribution Agreement With ScreenCell; Table 129: Horizon Discovery Enters Into Co-Development Agreement With Promega; Table 130: Stemina Biomarker Discovery Enters Into Co-Development Agreement With ILS; Table 131: Psyche Systems Enters Into Technology Integration Agreement With Aperio Technologies; Table 132: Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals; Table 133: PrognosDx Health Entetrs Into Co-Development Agreement With Accium BioSciences; Table 134: The Molecular Sciences Forms Joint Venture With VTT Technical Research; Table 135: DxTerity Diagnostics Enters Into Technology Integration Agreement With Caliper Life Sciences; Table 136: Gold Standard Diagnostics Extends Distribution Agreement With Fujirebio Diagnostics; Table 137: New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics; Table 138: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics; Table 139: Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center; Table 140: Absorption Systems Enters Into Co-Development Agreement With Temple University And Washington State University; Table 141: Oasis Diagnostics Enters Into Licensing Agreement With Two Researchers; Table 142: Bioo Scientific Enters Into Co-Development Agreement With JungWoo; Table 143: Accelr8 Technology Amends Licensing Agreement With SCHOTT; Table 144: Orion Genomics Enters Into Licensing Agreement With QIAGEN; Table 145: Quantum Materials Enters Into Technology Integration Agreement With Nanoaxis; Table 146: RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation; Table 147: SuviCa Enters Into Licensing Agreement With University of Colorado; Table 148: Polymedco Enters Into Distribution Agreement With Cardinal Health; Table 149: Universal Biosensors Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics; Table 150: LI-COR Biosciences Enters Into Licensing Agreement With Johns Hopkins University; Table 151: QIAGEN Enters Into Co-Development Agreement With Eli Lilly; Table 152: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute; Table 153: Lumora Enters Into Licensing Agreement With 3M; Table 154: NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute; Table 155: Biocept Enters Into Co-Marketing Agreement With Clarient; Table 156: Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical; Table 157: DNA Diagnostics Center Enters Into Licensing Agreement; Table 158: Pronexus Enters Into Technology Integration Agreement With RealityCorp; Table 159: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific; Table 160: EPIC Enters Into Distribution Agreement With Micro Imaging Technology; Table 161: BD Diagnostics Enters Into Co-Development Agreement With Lab21; Table 162: Procognia Enters Into Co-Development Agreement With Caerus Discovery; Table 163: BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne; Table 164: Hycor Biomedical Signs Licensing Agreement With Axis-Shield; Table 165: Thermo Fisher Scientific Enters Into Licensing Agreement With Alere; Table 166: Quanterix Enters Into Co-Development Agreement With Sony DADC; Table 167: Canon U.S. Life Sciences Enters Into Co-Development Agreement With The University of Maryland; Table 168: Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen; Table 169: Rhoen-Klinikum Enters Into Co-Development Agreement With Siemens; Table 170: Proteome Sciences Enters Into Collaboration With Buck Institute; Table 171: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical; Table 172: Gold Standard Diagnostics Enters Into Distribution Agreement With Fujirebio Diagnostics; Table 173: Roche NimbleGen Enters Into Co-Marketing Agreement With Caliper Life Sciences; Table 174: Clinical Genomics Extends Its Licensing Agreement With Quest Diagnostics; Table 175: LaserGen Enters Into Co-Development Agreement With National Instruments; Table 176: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center; Table 177: Metamark Genetics Enters Into Co-Development Agreement With Definiens; Table 178: Allegro Diagnostics Enters Into Licensing Agreement With Boston University And The University of Utah; Table 179: Signal Genetics Enters Into Research And Development Agreement With DiagnoCure; Table 180: Atherotech Diagnostics Enters Into Co-Marketing Agreement With GlycoMark; Table 181: Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement; Table 182: Mayo Clinic Enters Into Licensing Agreement With Rheonix; Table 183: ResearchDx Enters Into Partnership With CompanDX; Table 184: Enzo Clinical Enters Into Co-Marketing Agreement With IncellDx; Table 185: Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina; Table 186: F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck; Table 187: Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics; Table 188: Roche Enters Into Co-Development Agreement With Clovis Oncology; Table 189: Molecular Response Enters Into An Agreement With Scripps Translational Science Institute; Table 190: SAIC-Frederick Enters Into An Agreement With Biomatrica
1.2 List of Figures: Figure 1: In Vitro Diagnostics, Market Segmentation; Figure 2: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017; Figure 3: In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2010; Figure 4: In Vitro Diagnostics Market, United States, Category Contribution (%), 2010; Figure 5: In Vitro Diagnostics, United States, Cross-Category Analysis, 2003-2017; Figure 6: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010; Figure 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017; Figure 8: In Vitro Diagnostics, United States, Company share (%), 2010; Figure 9: Clinical Chemistry, Market Segmentation; Figure 10: Clinical Chemistry Market, United States, Revenue Mix ($m), 2010; Figure 11: Clinical Chemistry Market, United States, Segment Contribution (%), 2010; Figure 12: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 13: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 14: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 15: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 16: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 17: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 18: Clinical Chemistry, United States, Company share (%), 2010; Figure 19: Genetic Testing, Market Segmentation; Figure 20: Genetic Testing Market, United States, Revenue Mix ($m), 2010; Figure 21: Genetic Testing Market, United States, Segment Contribution (%), 2010; Figure 22: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 23: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 24: Genetic Testing, United States, Company share (%), 2010; Figure 25: Haematology, Market Segmentation; Figure 26: Haematology Market, United States, Revenue Mix ($m), 2010; Figure 27: Haematology Market, United States, Segment Contribution (%), 2010; Figure 28: Haematology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 29: Haematology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 30: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 31: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 32: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 33: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 34: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 35: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 36: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 37: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 38: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 39: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 40: Haematology, United States, Company share (%), 2010; Figure 41: Histology and Cytology, Market Segmentation; Figure 42: Histology And Cytology Market, United States, Revenue Mix ($m), 2010; Figure 43: Histology And Cytology Market, United States, Segment Contribution (%), 2010; Figure 44: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 45: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 46: Histology And Cytology, United States, Company share (%), 2010; Figure 47: Immuno Chemistry Market, United States, Revenue Mix ($m), 2010; Figure 48: Immuno Chemistry Market, United States, Segment Contribution (%), 2010; Figure 49: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 50: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 51: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 52: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 53: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 54: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 55: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 56: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 57: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 58: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 59: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 60: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 61: Immuno Chemistry, United States, Company share (%), 2010; Figure 62: Infectious Immunology, Market Segmentation; Figure 63: Infectious Immunology Market, United States, Revenue Mix ($m), 2010; Figure 64: Infectious Immunology Market, United States, Segment Contribution (%), 2010; Figure 65: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 66: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 67: Infectious Immunology, United States, Company share (%), 2010; Figure 68: Microbiology Culture, Market Segmentation; Figure 69: Microbiology Culture Market, United States, Revenue Mix ($m), 2010; Figure 70: Microbiology Culture Market, United States, Segment Contribution (%), 2010; Figure 71: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010; Figure 72: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017; Figure 73: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010; Figure 74: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017; Figure 75: Microbiology Culture, United States, Company share (%), 2010; Figure 76: Abbott Laboratories, Company Share (%),United States In Vitro Diagnostics Market, 2010; Figure 77: Siemens Healthcare, Company Share (%),United States In Vitro Diagnostics Market, 2010; Figure 78: F. Hoffmann-La Roche Ltd., Company Share (%),United States In Vitro Diagnostics Market, 2010; Figure 79: Beckman Coulter, Inc., Company Share (%),United States In Vitro Diagnostics Market, 2010; Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),United States In Vitro Diagnostics Market, 2010; Figure 81: bioMerieux S.A., Company Share (%),United States In Vitro Diagnostics Market, 2010

United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Share this report

Other tasks

Research Assistance

Related Markets

Microbiology & Virology Reports

Free Alert Me service